COVID-19

(044) The Impact of External Factors on Spontaneous Reporting Practices: A Time Series Analysis of FAERS Data

(045) Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

(046) Differences in Time to Onset Between Spontaneous Reports and Cohort Studies: The Case of the COVID-19 Vaccines

(047) Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries

(048) Effectiveness of 2-dose COVID-19 Vaccination Against SARS-CoV-2 Infection and Severe Outcomes in Cancer Patients

(049) The role of comorbidities in the development of AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands

(050) The Characteristics of Abnormal Uterine Bleeding Reports Following COVID-19 Vaccination

(051) Background rates of cardiovascular events in patients at high risk of severe COVID-19 before and during the COVID-19 pandemic

(052) Adverse post-vaccination events reported with anti-COVID-19 vaccines in Burkina Faso: analysis of spontaneous reports

(053) COVID 19 vaccine associated thromboembolic events-A VAERS database study

(054) COVID-19-related Pharmacovigilance Surveillance Based On A Spontaneous Reporting Database

(055) Time-to-onset of glomerular diseases following COVID-19 vaccination: a case series analysis

(056) Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya

(057) Assessment of COVID-19 vaccine-related adverse events in VigiAccess

(058) The challenges and lessons learnt from conducting COVID-19 monitoring studies through VAC4EU: coordination and management perspective

(059) Discovering the Risk Factors of the COVID-19 Vaccine-induced Carditis applying the Machine Learning Approach: Based on Real World Data

(060) National U.S. Claims-Based Cohort Study of the Safety of Adenoviral Vector COVID-19 Vaccination during Pregnancy

(061) Assessment of COVID-19 and Mpox Vaccine Data when Supplementing Administrative Claims with Immunization Information System Data

(062) Factors Associated With Influenza and COVID-19 Vaccination in Older Adults

(063) Vaccination Use among Pregnant Women 2016-2022: An Analysis Using Healthcare Claims

(064) Monitoring Results From a Postapproval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States: Vaccine Utilization and Incidence Rates of Myocarditis/Pericarditis

(065) COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network

(066) Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS Study

(067) Validation of a Claims-based Algorithm for Myocarditis/Pericarditis using Medical Chart Review

(068) Safety & immUnogenicity of COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED): Preliminary Results of 1031 Patients

(069) Identification and characterization of patients receiving a 1st booster of COVID-19 vaccines in a US administrative database

(070) Medical chart review of selected adverse event of special interest (AESI) to support rapid safety assessment of the Janssen COVID-19 vaccine (JCOVDEN): a validation study using US electronic health records and claims data

(071) Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 Vaccines in Four Large US National Insurers

(072) Waning vaccine response after primary vaccine series: Results from the COVID19 VaccinE Response in Rheumatology patients (COVER) study

(073) Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS Study

(074) Safety of COVID-19 Vaccines Among People With Prior History Of SARS-Cov-2 Infection: Results From the COVID-Vaccine-Monitor Cohort Event Monitoring

(075) The Adverse Events Following COVID-19 Vaccination – A Two-year Surveillance conducted in a sentinel site in south India

(076) Behaviors and associated determinants of COVID-19 vaccine acceptance and advocacy: a nationwide survey of pharmacy professionals using the Theoretical Domains Framework

(077) Updated Real-World Safety of the Pfizer-BioNTech COVID-19 Vaccine in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry

(078) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data: Methods and Results of the First Study Feasibility Assessment

(079) Vaccines effectiveness against hospitalizations ‘for’ and ‘with’ COVID-19, after clinical histories review

(080) Implementation of childhood immunization registry – a post-pandemic intervention to Track the immunization gaps created during COVID-19

(081) An Analysis Of The Impact Of The COVID-19 Pandemic Outbreak On Incident Patient Diagnoses In Primary Care In England Using An Interrupted Time Series

(082) Visualizing Discrepancies Between a Body of Trials and a Real-World Population: An Example from the COVID-19 Pandemic

(083) Definitions of Long COVID Among Published Research Studies

(084) Real World Effectiveness of Anticoagulation in Hospitalized COVID-19 Patients using High-Resolution EHR Data in the Presence of Time-varying Confounding: Out with the Old, In with the New

(085) Inhaled corticosteroid prescription patterns in UK primary care before and during the COVID-19 pandemic in patients with COPD

(086) Inaccuracy of Using ICD-10-CM Diagnosis Code U07.1 to Identify Outpatients with COVID-19 in US Claims Data

(087) Risk Prediction of Long COVID with Machine Learning in a Real-World Setting

(088) Linking real world data to assess risk of post-acute outcomes following COVID-19 infection in England: the ECHOES national surveillance system

(089) Clinical characteristics and healthcare resource utilization among patients identified with post-acute sequelae of COVID-19 (long-COVID) in US administrative claims data

(090) Validation of severe COVID-19 information recorded in BIFAP

(091) Assessing COVID-19’s impact on condition measurement in claims data

(092) Ursodeoxycholic acid may be a new protective factor for severe COVID-19 outcomes – evidence from a nationwide Swedish register-based cohort study within the SCIFI-PEARL project

(093) Rapid Production of Pharmacoepidemiology Results to Inform Regulatory Decision-making: Lessons Learned from the COVID-19 Pandemic

(094) High dose dexamethasone for COVID-19 not common in a large US hospital network

(095) Pilot Surveillance of Infant Lower Respiratory Tract Infections and Respiratory Syncytial Virus in the United States During the COVID Pandemic

(096) Association of Xuebijing treatment with clinical outcomes in COVID-19 patients: a retrospective cohort study with propensity score matching

(097) The Impact of the COVID-19 Pandemic on the Burden of Opioid Toxicity Deaths Across Canada

(098) COVID-19 Infection and Medicines in Pregnancy in Canada

(099) Association between race and COVID-19 outcomes in the United States (2020-2021)

(100) Timing and Duration of Remdesivir Treatment Among Individuals Hospitalized due to COVID-19 in the Capital Region of Denmark

(101) The impact of prenatal maternal mental health during the COVID-19 pandemic on birth outcomes: A study within the CONCEPTION cohort

(102) Rise of Underscreening of Depression Post COVID-19 in the US

(103) Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19 - An analysis from a population-based cohort within the SCIFI-PEARL project

(104) Validation of COVID-related ICD-10-CM Symptom Codes in Electronic Health Records

(105) Impact of the COVID-19 pandemic on initiation of anti-diabetic drug consumption pattern in Sweden - An interrupted time series study

(106) FACTORS ASSOCIATED WITH SELF-MEDICATION DURING THE COVID-19 PANDEMIC IN CHINCHA – PERU: A CROSS-SECTIONAL STUDY

(107) Impact of the COVID-19 Pandemic on Use of Medication and Healthcare Services Among Individuals with Intellectual and Developmental Disabilities in Ontario, Canada

(108) Impact of COVID-19 Pandemic on Leukotriene Receptor Antagonists Prescribing

(109) Long COVID symptoms following primo- vs reinfection: a multinational cohort analysis of primary care records from Catalonia and the UK

(110) Antibacterial Drug Use Among Hospitalized Patients with COVID-19 During Successive Epidemic Waves in Hong Kong

(111) Utilization of Telemedicine and antibiotic dispensing before and during the COVID-19 pandemic

(112) Postpartum depressive symptoms among Danish new mothers and fathers before and during the COVID-19 pandemic

(113) Clinical and Economic Characteristics of Patients Diagnosed with Long COVID: Early Findings from Real-World Data

(114) Thromboembolism Risk and Management Pattern in Hospitalized COVID-19 Patients: A Single-Center Experience in Ethiopia

(115) Racial and Ethnic Differences in Hospitalized and Critical COVID-19 Treatment, January 2021-April 2022

(116) Rates of Antidepressant, Antiepileptic and Anxiolytic Prescribing Among People Living with Dementia During the COVID-19 Pandemic: A Multinational Interrupted Time-Series Analysis

(117) Disparities in prescriptions medications use by socioeconomic status and geographical location during COVID-19 pandemic

(118) Pediatric and Adolescent Medication Use Before and During COVID-19: A Population-Based Cohort Study in Manitoba, Canada

(119) Establishing and Characterising Large COVID-19 Cohorts After Mapping the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model

(120) Convalescent Plasma Utilization Among Inpatient U.S. Medicare Beneficiaries Ages 65 and Older Diagnosed with COVID-19 During 2020-2021

(121) Characterization of Long COVID among U.S. Medicare Beneficiaries using Claims Data

(122) Changes in systemic cancer therapy in Australia during the later COVID-19 pandemic (2020 – 2022): a population-based study

(123) Risk of Post-Acute Sequelae of COVID (PASC) Among Patients With Type 2 Diabetes Mellitus on Various Anti-Diabetic Drug Classes

(124) The Missing Claimants of the Pandemic: Who Went Without Claims in Canada During the First Two Years of the COVID-19 Pandemic and what Does it Mean for Public and Private drug plans?

(125) Impact of COVID-19 on Hormonal Contraceptive Dispensing in Kentucky: An Interrupted Time Series Design

(126) Pregnancy during a pandemic: pregnancy occurrence and outcomes during the SARS-CoV-2 pandemic

(127) Characteristics of Pregnant People Treated With Sotrovimab for COVID-19 from the COVID-19 International Drug Pregnancy Registry (COVID-PR)

(128) Identifying fit-for-purpose existing data sources for COVID-19 pre-exposure prophylaxis in pregnancy

(129) Characteristics of data collected in MID-NET®

(130) Baseline characteristics of patients with chronic kidney disease and type 2 diabetes (CKD-T2D) initiating anti-hyperglycemic medication: differences before and during the outbreak of COVID-19 in US and UK

(131) Depression among Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients before and during the COVID-19 Pandemic Era: a US-claims Based Analysis

(132) Efficacy and safety of Remdesivir in COVID-19 patients: An overview of meta-Analysis

(133) Immunosuppressive therapy and covid-19-related hospitalization in solid organ transplant recipients: a French nationwide cohort study

(134) Medication Delivery Incidents Reported in Community Pharmacies in Canada: A pre- and post- pandemic analysis

(136) Quality of Adverse Events Reporting in Clinical Trials of COVID-19 Drugs: a systematic review

(137) The Impact of the COVID lock-down on transitions from a once-monthly parenteral therapy for osteoporosis in the U.S. Medicare program

(138) Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting

(139) Background Rates of Pediatric-Onset Type I Diabetes Before and During the COVID-19 Pandemic

(140) Systemic Steroids and its Combination with Remdesivir in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

(141) Using administrative data to understand substance misuse patterns in understudied populations: A child welfare sample

(142) Focus on types of risk minimization measures for carditis, associated with COVID-19 vaccines- FAERS Database Analysis

(143) The Impact of COVID-19 on Mental Health of Health Sciences Students in India: A Survey-Based Study